Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Expanded Access Lanadelumab in Japanese Hereditary Angioedema
jRCT2031200255Completed
- Sponsor
- Takeda
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of lanadelumab in hereditary angioedema (HAE), sponsored by Takeda. Primary endpoints: Number of participants with treatment-emergent adverse events, Number of participants with clinically significant abnormalities in clinical laboratory tests and 1 more. Started Feb 2021; status: completed.
02
Drugs
lanadelumab
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on jRCT2031200255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200255.